Virios Therapeutics to Merge with Wex Pharmaceuticals, Creating Dogwood Therapeutics

Virios Therapeutics has announced plans to merge with Wex Pharmaceuticals, leading to the formation of a new entity called Dogwood Therapeutics. This strategic move aims to combine the strengths and resources of both companies to accelerate the development of innovative therapies. The merger is expected to enhance the capabilities of Dogwood Therapeutics in addressing unmet medical needs and advancing its research agenda. Stakeholders are optimistic about the potential synergies that will arise from this collaboration, paving the way for groundbreaking advancements in therapeutic solutions.